查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301075

乳腺癌药物市场规模、份额及趋势分析报告：按治疗方法（靶向治疗、激素治疗）、按分销渠道（医院药房、零售药房）、按癌症类型（激素受体、HER2+）、细分市场预测，2023- 2030年

Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Therapy (Targeted, Hormonal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Cancer Type (Hormone Receptor, HER2+), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

乳腺癌药物市场增长和趋势

根据Grand View Research, Inc.最新报告，2023年至2030年全球乳腺癌药物市场规模将以9.09%的复合年增长率增长， 2030年预计到2020年将达到586.9亿美元。

这种增长主要是由疾病患病率上升、研发投资增加以及知名公司的举措推动的。 此外，个性化医疗的趋势正在推动市场增长，即根据患者的基因构成为个体患者量身定制治疗方案。 基因组学和分子生物学的进步促进了靶向疗法的发展，这些疗法比传统化疗更有效且副作用更少。 世界各国政府都在投资新药和治疗方法的研发。 例如，美国国家癌症研究所就设立了多个研究所。

例如，国家癌症研究所启动了多项研究计划来开发新药并提高现有治疗方法的有效性。 同样，2023年1月，澳大利亚政府宣布将投资1601万美元用于开发针对女性的治疗方法。 该投资将通过国家健康和医学研究委员会的资助计划资助 23 个项目，包括乳腺癌研究。 非营利组织的参与增加预计将推动市场的增长。 例如，2022 年 6 月，乳腺癌组织 Susan G. Komen 宣布将获得 2100 万美元，用于支持 26 个学术机构的约 48 个研究项目。 大部分资金将用于侵袭性乳腺癌的研究，随后进行临床试验和研究以缩小差距。

此外，乳腺癌患者也受到了这一流行病的影响，因为他们的免疫系统较弱，导致他们患 COVID-19 并发症的风险增加。 结果，许多患者不得不推迟或取消治疗，影响了对该药物的需求。 此外，疫情对经济的影响也对市场产生了影响。 失业和收入水平下降影响了购买药品的能力。 结果，产品需求下降，对市场产生中短期影响。 药品价格对市场影响较大。 较高的价格可能会限制使用并影响需求，而较低的价格可能会增加可用性并增加需求。 因此，利益相关者必须平衡对负担得起的药物的需求与持续研究和开发以改善治疗选择的需求。

乳腺癌药物市场报告亮点

  • 免疫治疗类型将成为2022年市场增长最快的治疗领域之一。 免疫疗法通过刺激患者的免疫系统识别和攻击癌细胞来发挥作用。 这种方法在包括乳腺癌在内的各种类型的癌症中都显示出了有希望的结果。
  • 按类型划分，激素受体细分市场在 2022 年占据了大部分市场份额。 激素受体阳性乳腺癌是最常见的亚型。 因此，激素治疗药物是治疗的主要手段。
  • 2022 年，医院药房分销渠道占据最大份额。 医院药房通常比零售药房和其他渠道提供更广泛的专科药物和治疗方法。
  • 不断上升的乳腺癌患病率、高昂的医疗保健支出以及持续的研发工作将使北美在 2022 年占据全球行业的主导地位。

内容

第一章调查方法及范围

  • 市场细分
  • 市场定义和目的
  • 调查方法
  • 信息获取
    • 购买的数据库
    • Gvr 内部数据库
    • 次要信息
    • 初步调查
  • 信息或数据分析
    • 数据分析模型
  • 市场形成和验证
  • 型号详细信息
    • 产品流分析
  • 辅助信息列表
  • 缩写列表
  • 主要信息列表

第 2 章执行摘要

  • 市场概况
  • 治疗和癌症类型快照
  • 分销渠道快照
  • 竞争格局快照

第三章市场变量、趋势和范围

  • 市场细分和范围
  • 市场体系展望
    • 母公司市场前景
    • 相关/补充市场前景
  • 市场趋势和展望
  • 市场动态
    • 全球癌症发病率和患病率不断上升
    • 大量投资于研发
    • 癌症生物学和药理学的技术进步
  • 市场製约因素分析
    • 严格的监管准则
    • 专利药品的有效期
    • 与化疗相关的并发症
  • 2022 年采用率和增长前景图
  • 商业环境分析
    • SWOT 分析：按因素（政治/法律、经济/技术）
    • 波特五力分析
  • COVID-19 的影响分析

第 4 章治疗业务分析

  • 乳腺癌药物市场：治疗变化分析
  • 靶向治疗
    • 乳腺癌药物市场，靶向治疗，2018-2030 年（百万美元）
    • Abemasiclib
    • Ado-曲妥珠单抗 emtansine
    • 依维莫司
    • 曲妥珠单抗
    • Ribociclib
    • 帕博西尼
    • 帕妥珠单抗
    • 奥拉帕尼
    • 其他
  • 激素疗法
    • 乳腺癌药物市场，激素治疗，2018-2030 年（百万美元）
    • 选择性雌激素受体调节剂 (Serms)
    • 芳香□抑製剂
    • 雌激素受体下调剂 (Erds)
  • 化疗
    • 乳腺癌药物市场，化疗，2018-2030 年（百万美元）
  • 免疫治疗
    • 乳腺癌药物市场，免疫疗法，2018-2030 年（百万美元）

第五章癌症类型业务分析

  • 乳腺癌药物市场：癌症类型的变异分析
  • 激素受体
    • 乳腺癌药物市场，激素受体，2018-2030 年（百万美元）
  • 她2+
    • 乳腺癌药物市场，HER2+，2018-2030（百万美元）

第六章分销渠道业务分析

  • 乳腺癌药物市场：分销渠道波动分析
  • 医院药房
    • 乳腺癌药物市场，医院药房，2018-2030 年（百万美元）
  • 零售药店
    • 乳腺癌药物市场，零售药房，2018-2030 年（百万美元）
  • 其他
    • 乳腺癌药物市场，其他，2018-2030 年（百万美元）

第七章区域业务分析

  • 2022 年和 2030 年按地区划分的乳腺癌药物市场份额
  • 北美
    • SWOT分析
    • 2018-2030 年北美乳腺癌药物市场（按治疗方法）（百万美元）
    • 2018-2030 年北美乳腺癌药物市场（按癌症类型划分）（百万美元）
    • 2018-2030 年北美乳腺癌药物市场（按分销渠道）（百万美元）
    • 美国
    • 加拿大
  • 欧洲
    • SWOT分析
    • 2018-2030 年欧洲乳腺癌药物市场（按疗法）（百万美元）
    • 2018-2030 年欧洲乳腺癌药物市场（按癌症类型）（百万美元）
    • 2018-2030 年欧洲乳腺癌药物市场（按分销渠道）（百万美元）
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • SWOT分析
    • 2018-2030 年亚太地区乳腺癌药物市场（按治疗方法）（百万美元）
    • 2018-2030 年亚太地区乳腺癌药物市场（按癌症类型）（百万美元）
    • 2018-2030 年亚太地区乳腺癌药物市场（按分销渠道）（百万美元）
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳大利亚
    • 泰国
  • 拉丁美洲
    • SWOT分析
    • 2018-2030 年拉丁美洲乳腺癌药物市场（按治疗方法）（百万美元）
    • 2018-2030 年拉丁美洲乳腺癌药物市场（按癌症类型划分）（百万美元）
    • 2018-2030 年拉丁美洲乳腺癌药物市场（按分销渠道）（百万美元）
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • SWOT分析
    • 2018-2030 年 MEA 乳腺癌药物市场（按治疗方法）（百万美元）
    • 2018-2030 年 MEA 乳腺癌药物市场（按癌症类型）（百万美元）
    • 2018-2030 年 MEA 乳腺癌药物市场（按分销渠道）（百万美元）
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第 8 章竞争格局

  • 公司分类
  • 战略规划
    • 推出新产品
    • 合作伙伴关係
    • 获取
    • 合作
    • 筹款
  • 2022 年公司市场份额分析
  • 公司简介
    • Novartis Ag
    • Pfizer, Inc
    • Merck Kgaa
    • Janssen Pharmaceuticals, Inc.
    • Celgene Corporation, Inc.
    • Genzyme Corporation
    • F. Hoffmann-La Roche Ltd
    • Astrazeneca
    • Abbvie Inc.
    • Bristol-Myers Squibb Company
    • Macrogenics, Inc.
    • Celldex Therapeutics
    • Onyx Pharmaceuticals Inc.

第9章 结论

Product Code: GVR-3-68038-041-5

Breast Cancer Drugs Market Growth & Trends

The global breast cancer drugs market size is expected to reach USD 58.69 billion by 2030, registering a CAGR of 9.09% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth is majorly attributed to the rising disease prevalence, increasing R&D investments, and initiatives by prominent players. Moreover, the trend towards personalized medicine, which involves tailoring treatment for individual patients based on their genetic makeup, is driving the growth of the market. Advances in genomics and molecular biology have led to the development of targeted therapies, which are more effective and have fewer side effects than traditional chemotherapy. Governments around the world are investing in the research and development of new drugs and treatment options. For instance, the U.S.

National Cancer Institute has established several research programs to develop new drugs and improve the efficacy of existing treatments. Similarly, in January 2023, the Australian government announced an investment of USD 16.01 million in developing targeted treatments for women. The investment is expected to fund 23 projects including research on breast cancer through a grant program by the National Health and Medical Research Council. The increasing participation of non-profit organizations is anticipated to propel the market growth. For instance, in June 2022, Susan G. Komen, a breast cancer organization, announced to receive USD 21 million to support around 48 research projects at 26 academic institutions. The majority of funds are allocated to research on aggressive breast cancers, followed by clinical trials and research on eliminating the disparities in the market.

Furthermore, breast cancer patients have been affected by the pandemic as the risk of complications from COVID-19 increases due to their weakened immune systems. As a result, many patients had to postpone or cancel their treatments, which affected the demand for drugs. Moreover, the economic impact of the pandemic also affected the market. The loss of employment or deduction in the income level impacted the affordability of drugs. This, in turn, resulted in reduced product demand and short to medium-term effects on the market. The cost of drugs has a significant impact on the market. High drug prices can limit their usage and affect demand, while lower prices can increase accessibility and demand. Thus, stakeholders need to balance the need for affordable drugs with the need for continued R&D to improve treatment options.

Breast Cancer Drugs Market Report Highlights

  • The immunotherapy type segment was one of the fastest-growing areas of therapy in the market in 2022. Immunotherapy works by stimulating the patient's immune system to recognize and attack cancer cells. This approach has shown promising results in a variety of types, including breast cancer
  • By type, the hormone receptor segment captured the majority of the market share in 2022. Hormone receptor-positive breast cancer is the most common subtype. As a result, hormone therapy drugs have been a mainstay of treatment
  • The hospital pharmacies distribution channel segment held the largest share in 2022. Hospital pharmacies often have access to a wide range of specialized drugs and therapies as compared to retail pharmacies or other channels
  • In terms of revenue share, North America had a dominant position in the global industry in 2022 owing to the increased prevalence of breast cancer, high healthcare expenditures, and ongoing R&D activities

Table of Contents

Chapter 1. Methodology And Scope

  • 1.1 Market Segmentation
  • 1.2 Market Definitions And Objectives
    • 1.2.1 Objective - 1
    • 1.2.2 Objective - 2
    • 1.2.3 Objective - 3
  • 1.3 Research Methodology
  • 1.4 Information Procurement
    • 1.4.1 Purchased Database
    • 1.4.2 Gvr's Internal Database
    • 1.4.3 Secondary Sources
    • 1.4.4 Primary Research
  • 1.5 Information Or Data Analysis
    • 1.5.1 Data Analysis Models
  • 1.6 Market Formulation & Validation
  • 1.7 Model Details
    • 1.7.1 Commodity Flow Analysis
  • 1.8 List Of Secondary Sources
  • 1.9 List Of Abbreviations
  • 1.10 List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Therapy And Cancer Type Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation And Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends And Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increased Incidence And Prevalence Rate Of Cancer Worldwide
    • 3.4.2. High Investment In R&D
    • 3.4.3. Technological Advancement In Cancer Biology & Pharmacology
  • 3.5. Market Restraint Analysis
    • 3.5.1. Stringent Regulatory Guidelines
    • 3.5.2. Expiry Of Patented Drugs
    • 3.5.3. Complications Associated With Chemotherapy
  • 3.6. Penetration And Growth Prospect Mapping 2022
  • 3.7. Business Environment Analysis
    • 3.7.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. Covid-19 Impact Analysis

Chapter 4. Therapy Business Analysis

  • 4.1. Breast Cancer Drugs Market: Therapy Movement Analysis
  • 4.2. Targeted Therapy
    • 4.2.1. Breast Cancer Drugs Market, Targeted Therapy, 2018 - 2030 (USD Million)
    • 4.2.2. Abemaciclib
      • 4.2.2.1. Breast Cancer Drugs Market, Abemaciclib, 2018 - 2030 (USD Million)
    • 4.2.3. Ado-Trastuzumab Emtansine
      • 4.2.3.1. Breast Cancer Drugs Market, Ado-Trastuzumab Emtansine, 2018 - 2030 (USD Million)
    • 4.2.4. Everolimus
      • 4.2.4.1. Breast Cancer Drugs Market, Everolimus, 2018 - 2030 (USD Million)
    • 4.2.5. Trastuzumab
      • 4.2.5.1. Breast Cancer Drugs Market, Trastuzumab, 2018 - 2030 (USD Million)
    • 4.2.6. Ribociclib
      • 4.2.6.1. Breast Cancer Drugs Market, Ribociclib, 2018 - 2030 (USD Million)
    • 4.2.7. Palbociclib
      • 4.2.7.1. Breast Cancer Drugs Market, Palbociclib, 2018 - 2030 (USD Million)
    • 4.2.8. Pertuzumab
      • 4.2.8.1. Breast Cancer Drugs Market, Pertuzumab, 2018 - 2030 (USD Million)
    • 4.2.9. Olaparib
      • 4.2.9.1. Breast Cancer Drugs Market, Olaparib, 2018 - 2030 (USD Million)
    • 4.2.10. Others
      • 4.2.10.1. Breast Cancer Drugs Market, Others, 2018 - 2030 (USD Million)
  • 4.3. Hormonal Therapy
    • 4.3.1. Breast Cancer Drugs Market, Hormonal Therapy, 2018 - 2030 (USD Million)
    • 4.3.2. Selective Estrogen Receptor Modulators (Serms)
      • 4.3.2.1. Breast Cancer Drugs Market, Selective Estrogen Receptor Modulators (Serms), 2018 - 2030 (USD Million)
    • 4.3.3. Aromatase Inhibitors
      • 4.3.3.1. Breast Cancer Drugs Market, Aromatase Inhibitors, 2018 - 2030 (USD Million)
    • 4.3.4. Estrogen Receptor Down Regulators (Erds)
      • 4.3.4.1. Breast Cancer Drugs Market, Estrogen Receptor Down Regulators (Erds), 2018 - 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Breast Cancer Drugs Market, Chemotherapy, 2018 - 2030 (USD Million)
  • 4.5. Immunotherapy
    • 4.5.1. Breast Cancer Drugs Market, Immunotherapy, 2018 - 2030 (USD Million)

Chapter 5. Cancer Type Business Analysis

  • 5.1. Breast Cancer Drugs Market: Cancer Type Movement Analysis
  • 5.2. Hormone Receptor
    • 5.2.1. Breast Cancer Drugs Market, Hormone Receptor, 2018 - 2030 (USD Million)
  • 5.3. Her2+
    • 5.3.1. Breast Cancer Drugs Market, Her2+, 2018 - 2030 (USD Million)

Chapter 6. Distribution Channel Business Analysis

  • 6.1. Breast Cancer Drugs Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Breast Cancer Drugs Market, Hospital Pharmacies, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Breast Cancer Drugs Market, Retail Pharmacies, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Breast Cancer Drugs Market, Others, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Breast Cancer Drugs Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. Swot Analysis
    • 7.2.2. North America Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.2.3. North America Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.2.4. North America Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.2.5. U.S.
      • 7.2.5.1. Key Country Dynamics
      • 7.2.5.2. Target Disease Prevalence
      • 7.2.5.3. Competitive Scenario
      • 7.2.5.4. Regulatory Framework
      • 7.2.5.5. Reimbursement Scenario
      • 7.2.5.6. U.S. Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.2.6. Canada
      • 7.2.6.1. Key Country Dynamics
      • 7.2.6.2. Target Disease Prevalence
      • 7.2.6.3. Competitive Scenario
      • 7.2.6.4. Regulatory Framework
      • 7.2.6.5. Reimbursement Scenario
      • 7.2.6.6. Canada Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Swot Analysis
    • 7.3.2. Europe Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.3.3. Europe Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.3.4. Europe Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.3.5. Germany
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Germany Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.6. Uk
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Uk Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.7. France
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. France Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.8. Italy
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Italy Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.9. Spain
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Spain Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.10. Denmark
      • 7.3.10.1. Key Country Dynamics
      • 7.3.10.2. Target Disease Prevalence
      • 7.3.10.3. Competitive Scenario
      • 7.3.10.4. Regulatory Framework
      • 7.3.10.5. Reimbursement Scenario
      • 7.3.10.6. Denmark Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.11. Sweden
      • 7.3.11.1. Key Country Dynamics
      • 7.3.11.2. Target Disease Prevalence
      • 7.3.11.3. Competitive Scenario
      • 7.3.11.4. Regulatory Framework
      • 7.3.11.5. Reimbursement Scenario
      • 7.3.11.6. Sweden Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.3.12. Norway
      • 7.3.12.1. Key Country Dynamics
      • 7.3.12.2. Target Disease Prevalence
      • 7.3.12.3. Competitive Scenario
      • 7.3.12.4. Regulatory Framework
      • 7.3.12.5. Reimbursement Scenario
      • 7.3.12.6. Norway Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Swot Analysis
    • 7.4.2. Asia Pacific Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.4.3. Asia Pacific Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.4.4. Asia Pacific Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.4.5. Japan
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. Japan Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.6. China
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. China Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.7. India
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. India Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.8. South Korea
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Target Disease Prevalence
      • 7.4.8.3. Competitive Scenario
      • 7.4.8.4. Regulatory Framework
      • 7.4.8.5. Reimbursement Scenario
      • 7.4.8.6. South Korea Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.9. Australia
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Target Disease Prevalence
      • 7.4.9.3. Competitive Scenario
      • 7.4.9.4. Regulatory Framework
      • 7.4.9.5. Reimbursement Scenario
      • 7.4.9.6. Australia Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.4.10. Thailand
      • 7.4.10.1. Key Country Dynamics
      • 7.4.10.2. Target Disease Prevalence
      • 7.4.10.3. Competitive Scenario
      • 7.4.10.4. Regulatory Framework
      • 7.4.10.5. Reimbursement Scenario
      • 7.4.10.6. Thailand Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Swot Analysis
    • 7.5.2. Latin America Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.5.3. Latin America Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.5.4. Latin America Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.5.5. Brazil
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Competitive Scenario
      • 7.5.5.4. Regulatory Framework
      • 7.5.5.5. Reimbursement Scenario
      • 7.5.5.6. Brazil Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.5.6. Mexico
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Competitive Scenario
      • 7.5.6.4. Regulatory Framework
      • 7.5.6.5. Reimbursement Scenario
      • 7.5.6.6. Mexico Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.5.7. Argentina
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Competitive Scenario
      • 7.5.7.4. Regulatory Framework
      • 7.5.7.5. Reimbursement Scenario
      • 7.5.7.6. Argentina Breast Cancer Drugs Market 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. Swot Analysis
    • 7.6.2. MEA Breast Cancer Drugs Market, By Therapy, 2018 - 2030 (USD Million)
    • 7.6.3. MEA Breast Cancer Drugs Market, By Cancer Type, 2018 - 2030 (USD Million)
    • 7.6.4. MEA Breast Cancer Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. South Africa Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.6. Saudi Arabia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Competitive Scenario
      • 7.6.6.4. Regulatory Framework
      • 7.6.6.5. Reimbursement Scenario
      • 7.6.6.6. Saudi Arabia Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.7. UAE
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Competitive Scenario
      • 7.6.7.4. Regulatory Framework
      • 7.6.7.5. Reimbursement Scenario
      • 7.6.7.6. UAE Breast Cancer Drugs Market 2018 - 2030 (USD Million)
    • 7.6.8. Kuwait
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Target Disease Prevalence
      • 7.6.8.3. Competitive Scenario
      • 7.6.8.4. Regulatory Framework
      • 7.6.8.5. Reimbursement Scenario
      • 7.6.8.6. Kuwait Breast Cancer Drugs Market 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New Product Launch
    • 8.2.2 Partnerships
    • 8.2.3 Acquisition
    • 8.2.4 Collaboration
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Novartis Ag
      • 8.4.1.1 Company Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product Benchmarking
      • 8.4.1.4 Strategic Initiatives
    • 8.4.2 Pfizer, Inc
      • 8.4.2.1 Company Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product Benchmarking
      • 8.4.2.4 Strategic Initiatives
    • 8.4.3 Merck Kgaa
      • 8.4.3.1 Company Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product Benchmarking
      • 8.4.3.4 Strategic Initiatives
    • 8.4.4 Janssen Pharmaceuticals, Inc.
      • 8.4.4.1 Company Overview
      • 8.4.4.2 Financial Performance
      • 8.4.4.3 Product Benchmarking
      • 8.4.4.4 Strategic Initiatives
    • 8.4.5 Celgene Corporation, Inc.
      • 8.4.5.1 Company Overview
      • 8.4.5.2 Financial Performance
      • 8.4.5.3 Product Benchmarking
      • 8.4.5.4 Strategic Initiatives
    • 8.4.6 Genzyme Corporation
      • 8.4.6.1 Company Overview
      • 8.4.6.2 Financial Performance
      • 8.4.6.3 Product Benchmarking
      • 8.4.6.4 Strategic Initiatives
    • 8.4.7 F. Hoffmann-La Roche Ltd
      • 8.4.7.1 Company Overview
      • 8.4.7.2 Financial Performance
      • 8.4.7.3 Product Benchmarking
      • 8.4.7.4 Strategic Initiatives
    • 8.4.8 Astrazeneca
      • 8.4.8.1 Company Overview
      • 8.4.8.2 Financial Performance
      • 8.4.8.3 Product Benchmarking
      • 8.4.8.4 Strategic Initiatives
    • 8.4.9 Abbvie Inc.
      • 8.4.9.1 Company Overview
      • 8.4.9.2 Financial Performance
      • 8.4.9.3 Product Benchmarking
      • 8.4.9.4 Strategic Initiatives
    • 8.4.10 Bristol-Myers Squibb Company
      • 8.4.10.1 Company Overview
      • 8.4.10.2 Financial Performance
      • 8.4.10.3 Product Benchmarking
      • 8.4.10.4 Strategic Initiatives
    • 8.4.11 Macrogenics, Inc.
      • 8.4.11.1 Company Overview
      • 8.4.11.2 Financial Performance
      • 8.4.11.3 Product Benchmarking
      • 8.4.11.4 Strategic Initiatives
    • 8.4.12 Celldex Therapeutics
      • 8.4.12.1 Company Overview
      • 8.4.12.2 Financial Performance
      • 8.4.12.3 Product Benchmarking
      • 8.4.12.4 Strategic Initiatives
    • 8.4.13 Onyx Pharmaceuticals Inc.
      • 8.4.13.1 Company Overview
      • 8.4.13.2 Financial Performance
      • 8.4.13.3 Product Benchmarking
      • 8.4.13.4 Strategic Initiatives

Chapter 9 Conclusion

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Breast Cancer Drugs Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 Global Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 6 Global Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 9 North America Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 10 North America Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 12 U.S. Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 15 Canada Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Canada Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 18 Canada Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 21 Europe Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 24 Germany Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 UK Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 27 UK Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 28 UK Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 30 France Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 31 France Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 33 Italy Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 36 Spain Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 39 Denmark Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 40 Denmark Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 42 Sweden Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 43 Sweden Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 45 Norway Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 46 Norway Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 52 China Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 53 China Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Japan Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 55 Japan Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 56 Japan Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 58 India Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 59 India Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 61 South Korea Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 62 South Korea Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 64 Australia Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 65 Australia Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 67 Thailand Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 68 Thailand Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 71 Latin America Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 72 Latin America Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 74 Brazil Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Mexico Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 77 Mexico Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 78 Mexico Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Argentina Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 80 Argentina Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 81 Argentina Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Breast Cancer Drugs Market, by Country, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 South Africa Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 87 South Africa Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 88 South Africa Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 90 Saudi Arabia Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 91 Saudi Arabia Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 UAE Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 93 UAE Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 94 UAE Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Breast Cancer Drugs Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Breast Cancer Drugs Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Breast Cancer Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 Financial performance
  • Table 99 Key companies undergoing expansions
  • Table 100 Key companies undergoing acquisitions
  • Table 101 Key companies undergoing collaborations
  • Table 102 Key companies launching new products/services
  • Table 103 Key companies undergoing partnerships
  • Table 104 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Breast Cancer Drugs Market Segmentation
  • Fig. 7 Market Snapshot, 2022
  • Fig. 8 Market Trends & Outlook
  • Fig. 9 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 15 Global Breast Cancer Drugs: By Therapy, Movement Analysis
  • Fig. 16 Global Breast Cancer Drugs Market, for Targeted Therapy, 2018 - 2030 (USD Million)
  • Fig. 17 Global Breast Cancer Drugs Market, for Abemaciclib, 2018 - 2030 (USD Million)
  • Fig. 18 Global Breast Cancer Drugs Market, for Ado-Trastuzumab Emtansine, 2018 - 2030 (USD Million)
  • Fig. 19 Global Breast Cancer Drugs Market, for Everolimus, 2018 - 2030 (USD Million)
  • Fig. 20 Global Breast Cancer Drugs Market, for Trastuzumab, 2018 - 2030 (USD Million)
  • Fig. 21 Global Breast Cancer Drugs Market, for Ribociclib2 018 - 2030 (USD Million)
  • Fig. 22 Global Breast Cancer Drugs Market, for Palbociclib, 2018 - 2030 (USD Million)
  • Fig. 23 Global Breast Cancer Drugs Market, for Pertuzumab, 2018 - 2030 (USD Million)
  • Fig. 24 Global Breast Cancer Drugs Market, for Olaparib, 2018 - 2030 (USD Million)
  • Fig. 25 Global Breast Cancer Drugs Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global Breast Cancer Drugs Market, for Hormonal Therapy, 2018 - 2030 (USD Million)
  • Fig. 27 Global Breast Cancer Drugs Market, for Selective Estrogen Receptor Modulators (SERMs), 2018 - 2030 (USD Million)
  • Fig. 28 Global Breast Cancer Drugs Market, for Aromatase Inhibitors, 2018 - 2030 (USD Million)
  • Fig. 29 Global Breast Cancer Drugs Market, for Estrogen Receptor Down regulators (ERDs), 2018 - 2030 (USD Million)
  • Fig. 30 Global Breast Cancer Drugs Market, for Chemotherapy, 2018 - 2030 (USD Million)
  • Fig. 31 Global Breast Cancer Drugs Market, for Immunotherapy, 2018 - 2030 (USD Million)
  • Fig. 32 Global Breast Cancer Drugs: Cancer Type, Movement Analysis
  • Fig. 33 Global Breast Cancer Drugs Market, for Hormone Receptor, 2018 - 2030 (USD Million)
  • Fig. 34 Global Breast Cancer Drugs Market, for HER2+, 2018 - 2030 (USD Million)
  • Fig. 35 Global Breast Cancer Drugs: Distribution Channel, Movement Analysis
  • Fig. 36 Global Breast Cancer Drugs Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 37 Global Breast Cancer Drugs Market, for Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 38 Global Breast Cancer Drugs Market, for Others2018 - 2030 (USD Million)
  • Fig. 39 Regional Marketplace: Key Takeaways Breast Cancer Drugs Market,
  • Fig. 40 Regional Outlook, 2022 & 2030 Breast Cancer Drugs Market,
  • Fig. 41 Global Breast Cancer Drugs Market, Region Movement Analysis
  • Fig. 42 North America Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 Canada Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 Europe Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 UK Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 France Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Sweden Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 Norway Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Asia Pacific Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 Japan Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 China Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 India Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 58 Australia Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 60 Thailand Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 61 Latin America Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 62 Brazil Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 63 Mexico Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 64 Argentina Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 65 Middle East and Africa Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 66 South Africa Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 67 Saudi Arabia Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 68 UAE Breast Cancer Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 69 Kuwait Breast Cancer Drugs Market, 2018 - 2030 (USD Million)